journal article·2021

Passive targeting of high-grade gliomas via the EPR effect: a closed path for metallic nanoparticles?

Carlos Caro, Ashish Avasthi, Jose M. Paez-Muñoz, Manuel Pernia Leal, María L. García-Martín

Biomaterials Science· Volume 9· Issue 23
Publisher page

Abstract

Passive tumor targeting via the enhanced permeability and retention (EPR) effect has long been considered the most effective mechanism for the accumulation of nanoparticles inside solid tumors. However, several studies have demonstrated that the EPR effect is largely dependent on the tumor type and location. Particularly complex is the situation in brain tumors, where the presence of the blood-brain tumor barrier (BBTB) adds an extra limiting factor in reaching the tumor interstitium. However, it remains unclear whether these restraints imposed by the BBTB prevent the EPR effect from acting as an efficient tumor targeting mechanism for metallic nanoparticles. In this work, we have studied the EPR effect of metallic magnetic nanoparticles (MMNPs) in a glioblastoma (GBM) model by parametric MRI. Our results showed that only MMNPs ≤50 nm could reach the tumor interstitium, whereas larger MMNPs were unable to cross the BBTB. Furthermore, even for MMNPs around 30-50 nm, the amount of them found within the tumor was scarce and restricted to the vicinity of large tumor vessels, indicating that the BBTB strongly limits the passive accumulation of metallic nanoparticles in brain tumors. Therefore, active targeting becomes the most reasonable strategy to target metallic nanoparticles to GBMs.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

BIONAND – Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía-Universidad de Málaga), C/Severo Ochoa, 35, 29590 Málaga, Spain

Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, 41012 Sevilla, Spain

Biomedical Research Networking Center in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Spain

Funding

Ministerio de Economía, Industria y Competitividad, Gobierno de España · Ministerio de Ciencia e Innovación · Consejería de Salud y Familias, Junta de Andalucía

References (63)

Show source-provided references
1. Young · Ann. Transl. Med. · 2015 · 3 · 121
2. Woehrer · Curr. Opin. Neurol. · 2014 · 27 · 66610.1097/WCO.0000000000000144 ↗
3. Krex · Brain: J. Neurol. · 2007 · 130 · 259610.1093/brain/awm204 ↗
4. Nizamutdinov · World Neurosurg. · 2018 · 109 · e6710.1016/j.wneu.2017.09.104 ↗
5. Stupp · Ann. Oncol. · 2014 · 25 · iii9310.1093/annonc/mdu050 ↗
6. Villanueva-Meyer · Neurosurgery · 2017 · 81 · 39710.1093/neuros/nyx103 ↗
7. Zhou · Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. · 2013 · 5 · 110.1002/wics.1239 ↗
8. Caravan · Chem. Rev. · 1999 · 99 · 229310.1021/cr980440x ↗
9. Kanda · Radiology · 2014 · 270 · 83410.1148/radiol.13131669 ↗
10. McDonald · Radiology · 2015 · 275 · 77210.1148/radiol.15150025 ↗
11. Lancelot · Invest. Radiol. · 2020 · 55 · 57810.1097/RLI.0000000000000684 ↗
12. Yan · Oncotarget · 2017 · 8 · 4349110.18632/oncotarget.16482 ↗
13. Stupp · Lancet Oncol. · 2009 · 10 · 45910.1016/S1470-2045(09)70025-7 ↗
14. Chang · Biochem. Biophys. Res. Commun. · 2015 · 468 · 51110.1016/j.bbrc.2015.10.136 ↗
15. Shi · Nat. Rev. Cancer · 2017 · 17 · 2010.1038/nrc.2016.108 ↗
16. Kim · Int. J. Nanomed. · 2020 · 15 · 571910.2147/IJN.S254774 ↗
17. Lim · Chem. Rev. · 2015 · 115 · 32710.1021/cr300213b ↗
18. Swain · Curr. Drug Delivery · 2016 · 13 · 129010.2174/1567201813666160713121122 ↗
19. Yu · Nanoscale Res. Lett. · 2021 · 16 · 8810.1186/s11671-021-03489-z ↗
20. Zhao · Theranostics · 2020 · 10 · 627810.7150/thno.42564 ↗
21. Avasthi · Top. Curr. Chem. · 2020 · 378 · 4010.1007/s41061-020-00302-w ↗
22. Zhou · Biomaterials · 2020 · 240 · 11990210.1016/j.biomaterials.2020.119902 ↗
23. Matsumura · Cancer Res. · 1986 · 46 · 6387
24. Kunjachan · Nano Lett. · 2014 · 14 · 97210.1021/nl404391r ↗
25. Maeda · Adv. Drug Delivery Rev. · 2015 · 91 · 310.1016/j.addr.2015.01.002 ↗
26. Maeda · J. Controlled Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
27. Caro · Curr. Pharm. Des. · 2015 · 21 · 482210.2174/1381612821666150820100812 ↗
28. Yao · Front. Mol. Biosci. · 2020 · 7 · 19310.3389/fmolb.2020.00193 ↗
29. Lugano · Cell. Mol. Life Sci. · 2020 · 77 · 174510.1007/s00018-019-03351-7 ↗
30. Cabral · Nat. Nanotechnol. · 2011 · 6 · 81510.1038/nnano.2011.166 ↗
31. Kang · Adv. Healthcare Mater. · 2020 · 9 · 190122310.1002/adhm.201901223 ↗
32. Kalyane · Mater. Sci. Eng., C · 2019 · 98 · 125210.1016/j.msec.2019.01.066 ↗
33. Longmire · Nanomedicine · 2008 · 3 · 70310.2217/17435889.3.5.703 ↗
34. van Tellingen · Drug Resist. Updates · 2015 · 19 · 110.1016/j.drup.2015.02.002 ↗
35. Sarin · J. Transl. Med. · 2008 · 6 · 8010.1186/1479-5876-6-80 ↗
36. Sarin · J. Transl. Med. · 2009 · 7 · 5110.1186/1479-5876-7-51 ↗
37. Schlageter · Microvasc. Res. · 1999 · 58 · 31210.1006/mvre.1999.2188 ↗
38. Blanco · Nat. Biotechnol. · 2015 · 33 · 94110.1038/nbt.3330 ↗
40. Siegal · J. Neurosurg. · 1995 · 83 · 102910.3171/jns.1995.83.6.1029 ↗
41. Jin · Bioconjugate Chem. · 2011 · 22 · 256810.1021/bc200406n ↗
42. Gelperina · Eur. J. Pharm. Biopharm. · 2010 · 74 · 15710.1016/j.ejpb.2009.09.003 ↗
43. Suárez-García · ACS Appl. Mater. Interfaces · 2018 · 10 · 3881910.1021/acsami.8b15594 ↗
44. Pernia Leal · RSC Adv. · 2015 · 5 · 7688310.1039/C5RA15680G ↗
45. Park · Nat. Mater. · 2004 · 3 · 89110.1038/nmat1251 ↗
46. Pozo-Torres · Soft Matter · 2020 · 16 · 325710.1039/C9SM02512J ↗
47. Stiufiuc · J. Nanomater. · 2013 · 2013 · 14603110.1155/2013/146031 ↗
48. Caro · Colloids Surf., B · 2019 · 177 · 25310.1016/j.colsurfb.2019.01.051 ↗
49. Wu · Int. J. Nanomed. · 2019 · 14 · 424710.2147/IJN.S201107 ↗
50. Caro · Methods Mol. Biol. · 2018 · 1718 · 40910.1007/978-1-4939-7531-0_24 ↗
51. Heye · NeuroImage Clin. · 2014 · 6 · 26210.1016/j.nicl.2014.09.002 ↗
52. Smirniotopoulos · Radiographics · 2007 · 27 · 52510.1148/rg.272065155 ↗
53. Barnes · Pharmaceutics · 2012 · 4 · 44210.3390/pharmaceutics4030442 ↗
54. Xue · Sci. Rep. · 2017 · 7 · 1389410.1038/s41598-017-14341-9 ↗
55. Nichols · J. Controlled Release · 2014 · 190 · 45110.1016/j.jconrel.2014.03.057 ↗
56. Danhier · J. Controlled Release · 2016 · 244 · 10810.1016/j.jconrel.2016.11.015 ↗
57. Guo · Nat. Commun. · 2018 · 9 · 13010.1038/s41467-017-02588-9 ↗
58. Hui · Sci. Adv. · 2020 · 6 · eaaz431610.1126/sciadv.aaz4316 ↗
59. Barth · J. Neuro-Oncol. · 2009 · 94 · 29910.1007/s11060-009-9875-7 ↗
60. Lope-Piedrafita · NMR Biomed. · 2008 · 21 · 79910.1002/nbm.1256 ↗
61. Lee · J. Nucl. Med. · 1985 · 26 · 72
62. Arvanitis · Nat. Rev. Cancer · 2020 · 20 · 2610.1038/s41568-019-0205-x ↗
63. Nichols · Nano Today · 2012 · 7 · 60610.1016/j.nantod.2012.10.010 ↗